N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Phase 4 N=777 ISCHEMIA-Chronic Kidney Disease Trial
Cardiovascular Diseases · Coronary Artery Disease · Heart Diseases
Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants
Phase 4 N=127 Responses of Myocardial Ischemia to Escitalopram Treatment
Myocardial Ischemia
Primary: Percentage of Participants With an Absence of Mental Stress-induced Myocardial Ischemia (MSIMI) During the 3 Mental Stressors — 34.2; 17.5 percentage of participants
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
Phase 4 N=28 Ranolazine in Ischemic Cardiomyopathy
Cardiomyopathy · Chest Pain · Dyspnea
Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058
Phase 3 N=40 Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Heart Disease, Ischemic · Atherosclerosis, Coronary
Primary: Magnetic Resonance Image Quality Rating — 3.57; 2.55 units on a likert scale — p=<0.001
Phase 4 N=697 Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease
Ischemic Heart Disease
Primary: Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement — 140 participants
N/A N=48 Perceived Social Support, Heart Rate Variability, and Hopelessness in Patients With Ischemic Heart Disease
Ischemic Heart Disease
Primary: State Hopelessness — 1.25 units on a scale — p=<0.05
Phase 2 N=92 Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)
Chronic Ischemic Heart Disease · Left Ventricular Dysfunction · Angina
Primary: Change in Maximal Oxygen Consumption (VO2max) — -0.6; 0.4 mL/kg/min — p=0.169
N/A N=5,269 Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications
Myocardial Ischemia · Rheumatic Diseases
Primary: Proportion of Days Covered (PDC) — 82.6; 75.6; 78.4; 73.3 percentage of days covered
Phase 2 N=323 Integrated Biomarker And Imaging Study - 2
Atherosclerosis
Primary: Mean Circulating High Sensitivity C- Reactive Protein (Hs-CRP) Levels at Week 52. — 1.034; 0.913 mg per litre (mg/L) — p=0.348
Phase 2 N=8 Healthy Heart Habits
Acute Coronary Syndrome · Depression
Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale
Early Phase 1 N=30 Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure
Heart Failure
Primary: Blood Flow — 300; 275 ml/min
N/A N=58 Disease Management for Coronary Artery Patients
Patient Empowerment · Coronary Artery Disease
Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale
Phase 2 N=103 The Neuroprotective Effect of Remote Ischemic Preconditioning on Ischemic Cerebral Vascular Disease
Cerebrovascular Disease
Primary: Blood Pressure and Heart Rates;
Phase 4 N=300 Clinical Study of Lipoic Acid on Ischemic Heart Failure
Ischemic Heart Failure
Primary: Number of Participants That Had First Occurrence of the Composite Endpoint — 32; 40 Participants
Phase 3 N=110 Myocardial Ischemia and Transfusion Pilot
Myocardial Infarction · Unstable Angina · Coronary Artery Disease
Primary: Hemoglobin Concentration — 10.30; 9.03; 10.78; 8.98 g/dL — p=<0.001
Phase 2 N=53 Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study
Critical Limb Ischemia
Primary: To Determine Platelet Inhibition Before and After Switching for Two Weeks From Clopidogrel to Ticagrelor in Patients With CLI. — 173; 140; 71; 63 P2Y12 reaction units…
Phase 2 N=20 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
Myocardial Ischemia
Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1
N/A N=266 Remote Ischemic Postconditioning in Humans
Myocardial Reperfusion Injury
Primary: Maximum Increase of Troponin at 24 Hours — 0.478; 0.476 ng/ml
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Phase 4 N=51 EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia
Ischemic Heart Disease
Primary: Epicardial Coronary Artery Endothelial Function (Adjusted) at Week 16 Comparing the Eplerenone Group to the Placebo Group — -1.2; -10.7 % change wk16-%change wk0…
Phase 2 N=6 Ranolazine Mediated PVC Reduction in Ischemic Heart Disease
Ventricular Premature Complexes · Myocardial Ischemia
Primary: The Effect of Ranolazine on the PVC Burden Over 30 Days — 5.71; 5.495 percentage of PVC burden
Phase 2 N=30 Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients
Atrial Fibrillation · Coronary Artery Disease
Primary: Sensitivity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD) — 80 Percentage of true positive cases
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 2 N=23 Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI
Myocardial Reperfusion Injury
Primary: Average Peak Velocity (APV) Immediately Following Percutaneous Coronary Intervention (PCI) — 30; 19 cm/s — p=0.029
N/A N=24 Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
Obesity
Primary: Net Tissue-type Plasminogen Activator (t-PA) Release — 0.24; 0.59; -0.38; 0.29 ng/min/100ml — p=0.04
Phase 2 N=20 Microvascular Coronary Disease In Women: Impact Of Ranolazine
Myocardial Ischemia
Primary: Cardiac Magnetic Resonance (CMRs) — 11.7; 16.0 Percentage of ischemic myocardium
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18